Tokyo, Jan. 1 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059620) titled 'Multicenter Cohort Study of Oncological Outcomes and Prognosis for Urothelial Carcinoma Treated by Chemotherapy in Ehime Prefecture' on Jan. 1.
Study Type:
Observational
Primary Sponsor:
Institute - NHO Shikoku Cancer Center
Condition:
Condition - Urotherial carcinoma
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - The goal of this study is to retrospectively analyze data from all institutions within the Ehime Prefecture Urological Society that have administered chemotherapy (anticancer drugs, immune checkpoint inhibitors, ADCs) to patients with urothelial carcinoma. The study will focus on clinical data, treatment outcomes, adverse events, and factors affecting treatment efficacy.
Basic objectives2 - Safety,Efficacy
Eligibility:
Age-lower limit - Not applicable
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Episode 1 (Data update only): The study will include patients with unresectable or metastatic urothelial carcinoma who received chemotherapy from December 1, 2017, to June 30, 2024, at institutions within the Ehime Prefecture Urological Society.
Episode 2: Patients of unresectable or metastatic urothelial carcinoma treated with chemotherapy between July 1, 2024, and December 31, 2026.
Key exclusion criteria - As this is an observational study, no specific exclusion criteria are stipulated.
Target Size - 400
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2025 Year 11 Month 01 Day
Anticipated trial start date - 2026 Year 01 Month 10 Day
Last follow-up date - 2028 Year 12 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068186
Disclaimer: Curated by HT Syndication.
